[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio39ff0b51":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio39ff0b51","渤健(BIIB)Q3财报超预期，罕见病药物销售强劲","\u002Fdoc\u002Fdcio39ff0b51","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>美股投资网获悉，渤健(BIIB)10月28日盘前发布第三季度业绩总营收28.04亿美元，同比增长11%，固定汇率情景下增长10%，高于市场预期的26.3亿至26.8亿美元;调整后摊薄每股收益2.62美元，高于预期约1.99美元，但同比下滑46%。公司罕见病和阿尔茨海默病药物的强劲需求帮助抵消了多发性硬化症治疗药物销售下滑的影响。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>受2.84亿美元收购在研项目(IPR&D)费用影响——主要来自对RayThera的收购——GAAP口径转为每股亏损0.14美元，上年同期为每股盈利3.17美元。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>公司单季自由现金流约6亿美元，季末净债务约64亿美元。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>业务结构上，成长组合营收12.6亿美元，同比大增49%，占核心制药营收比重升至63%SPINRAZA收入4.61亿美元，同比增长23%，LEQEMBI全球在售2.02亿美元，同比增长67%，本季首次完整并入的Apellis产品中SYFOVRE收入1.91亿美元，同比增长27%，注射量创上市以来新高。同期传统多发性硬化业务收入9.19亿美元，同比下降13%;生物类似药下降16%。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这家制药商正寄望于通过近期以56亿美元收购ApellisPharmaceuticals获得的Syfovre和Empaveli，以及其罕见病药物来推动增长，其定价压力正拖累其老化的多发性硬化症产品组合。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>眼科疾病药物Syfovre第三季度销售额增长27%，至1.91亿美元;肾病治疗药物Empaveli实现收入5200万美元，同比增长92%。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>其罕见病产品组合——包括遗传性疾病药物Skyclarys和脊髓性肌萎缩症药物Spinraza——本季度销售额为6.76亿美元，同比增长27%。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>首席执行官Christopher Viehbacher预计，未来一年即将公布的后期临床试验结果将支撑长期增长，未来12个月多项III期数据将陆续读出，其中litifilimab治疗红斑狼疮的顶线结果预计12月上旬公布。分析师指出，狼疮药物litifilimab和肾病治疗药物felzartamab是潜在增长驱动力。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>根据LSEG数据，其与卫材(Eisai)共同开发的阿尔茨海默病药物Leqembi全球销售额同比增长67%，至约2.02亿美元，超过分析师平均预期的1.306亿美元。渤健正期望Leqembi更方便的皮下注射剂型近期在美国获批来推动患者使用。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>渤健上调全年调整后每股收益指引下限，将2026年调整后利润预测下限上调20美分，预计每股12.20至13美元，此前预期为12至13美元。更新后区间的中点高于预期的12.36美元。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>最专业的美股资讯,推荐美股大数据 \u003Ca href=\"https:\u002F\u002FStockwe.com\u002F\">https:\u002F\u002FStockwe.com\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如何识别美股市场异常波动？美国机构主力资金买卖情况，出货和吸筹，使用美股投资网VIP会员，2008年成立于美国硅谷，由前纽约证券交易所分析师Ken创立，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化模型，建立了一个股市数据库 \u003Ca href=\"https:\u002F\u002FStockWe.com\u002F\">https:\u002F\u002FStockWe.com\u002F\u003C\u002Fa> 每天处理千万级股票数据：捕捉期权大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准交易信号第一时间发到您手机APP！\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FB\u002FBIIB\u002FBIIB.jpg","2026-10-28T17:48:06","2026.10.28","2026\u002F10\u002F28",47907,[22],"BIIB","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimages\u002Ffooter\u002Ffooter-1-wechat.gif?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-2-telegram.png?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-3-whatsapp.png?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-4-line.png?v=20260930c","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]